Blockbusters

Expected blockbusters: A year in progress

Earlier this year, we released the Cortellis Drugs to Watch 2019 report, which highlighted seven drugs expected to launch in 2019 and become blockbusters in 2023. We have subsequently reported on three of those drugs that have now gained approval, including Zolgensma which entered the market as the most expensive drug ever launched. Since that […]

Immune-related and genetic disorder products drive Cortellis Drugs to Watch 2019

Seven drugs are set to enter the market in 2019 and achieve blockbuster status by 2023, according to Cortellis Drugs to Watch 2019, from Clarivate Analytics. Therapies targeting diseases characterized by genetic disorder and/or excessive immune response (including autoimmunity) dominate the list, with six agents out of the seven, and a strong showing by orphan […]

Novo Nordisk’s Ozempic: Launch was late but sales forecasts climbing

This article is part of an ongoing blog series profiling the12 new, game-changing drugs predicted to achieve blockbuster status by 2022 in the 2018 edition of Drugs to Watch, the annual industry forecast and analysis from Clarivate Analytics. Read the full Drugs to Watch report here or follow the series for the latest updates. Drugs […]

Oncology, driven by the promise of IO, dominates biopharma deals landscape

Spurred by the promise of immuno-oncology (IO), oncology dominated the biopharma dealmaking landscape last year, a new article by Jamie Munro and Helen Dowden, of Clarivate Analytics, shows. The acute interest in IO continues a trend, the article noted: The technology has been a factor in 32 of the 35 multibillion-dollar oncology licensing deals over […]